These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10474685)

  • 1. Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates.
    McManus DT; Patterson AH; Maxwell P; Humphreys MW; Anderson NH
    Mol Pathol; 1999 Apr; 52(2):75-7. PubMed ID: 10474685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates.
    Mezzelani A; Alasio L; Bartoli C; Bonora MG; Pierotti MA; Rilke F; Pilotti S
    Br J Cancer; 1999 May; 80(3-4):519-25. PubMed ID: 10408862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
    Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
    Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interphase cytogenetic analysis of erbB2 and topoII alpha co-amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ.
    Murphy DS; McHardy P; Coutts J; Mallon EA; George WD; Kaye SB; Brown R; Keith WN
    Int J Cancer; 1995 Feb; 64(1):18-26. PubMed ID: 7665243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu amplification detected by fluorescence in situ hybridization in fine needle aspirates from primary breast cancer.
    Bozzetti C; Nizzoli R; Guazzi A; Flora M; Bassano C; Crafa P; Naldi N; Cascinu S
    Ann Oncol; 2002 Sep; 13(9):1398-403. PubMed ID: 12196365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
    Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
    Jimenez RE; Wallis T; Tabasczka P; Visscher DW
    Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
    Gu M; Ghafari S; Zhao M
    Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques.
    Ellis CM; Dyson MJ; Stephenson TJ; Maltby EL
    J Clin Pathol; 2005 Jul; 58(7):710-4. PubMed ID: 15976337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
    Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
    Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene copy mapping of the ERBB2/TOP2A region in breast cancer.
    Jacobson KK; Morrison LE; Henderson BT; Blondin BA; Wilber KA; Legator MS; O'Hare A; Van Stedum SC; Proffitt JH; Seelig SA; Coon JS
    Genes Chromosomes Cancer; 2004 May; 40(1):19-31. PubMed ID: 15034864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays.
    McCormick SR; Lillemoe TJ; Beneke J; Schrauth J; Reinartz J
    Am J Clin Pathol; 2002 Jun; 117(6):935-43. PubMed ID: 12047146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of HER2 gene expression status in breast cancer by fluorescence in-situ hybridization].
    Zeng X; Zhao DC; Zhou WX; Wu SF; Liang ZY; Liu TH
    Zhonghua Bing Li Xue Za Zhi; 2005 Nov; 34(11):701-5. PubMed ID: 16536311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17.
    Torrisi R; Rotmensz N; Bagnardi V; Viale G; Curto BD; Dell'orto P; Veronesi P; Luini A; D'Alessandro C; Cardillo A; Goldhirsch A; Colleoni M
    Eur J Cancer; 2007 Nov; 43(16):2339-44. PubMed ID: 17855075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid-based fluorescence in situ hybridization assay for detection of ERBB2 gene amplification in patients with breast cancer.
    Yeh CH; Whitmire WA; Albitar M
    Clin Chem; 2008 Nov; 54(11):1831-9. PubMed ID: 18787015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization for detecting erbB-2 amplification in breast tumor fine needle aspiration biopsies.
    Sauter G; Feichter G; Torhorst J; Moch H; Novotna H; Wagner U; Dürmüller U; Waldman FM
    Acta Cytol; 1996; 40(2):164-73. PubMed ID: 8629392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.
    Moelans CB; de Weger RA; van Diest PJ
    Breast Cancer Res Treat; 2010 Feb; 120(1):1-7. PubMed ID: 19760503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours.
    Laakso M; Tanner M; Isola J
    J Pathol; 2006 Sep; 210(1):3-9. PubMed ID: 16823892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.